Ubs Group Ag Janux Therapeutics, Inc. Transaction History

Ubs Group Ag

$397 Billion
Q1 2024

A detailed history of Ubs Group Ag transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 22,204 shares of JANX stock, worth $930,125. This represents 0.0% of its overall portfolio holdings.

Number of Shares

22,204

Holding current value

$930,125

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$7.93 - $49.75 $176,077 - $1.1 Million	22,204 New	22,204 $835,000
Q1 2023 May 12, 2023	BUY	$11.25 - $22.21 $7,065 - $13,947	628 Added 294.84%	841 $10,000
Q4 2022 Feb 08, 2023	BUY	$11.1 - $18.26 $2,364 - $3,889	213 New	213 $2,000
Q2 2022 Aug 10, 2022	SELL	$9.52 - $15.65 $33,320 - $54,775	-3,500 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$13.24 - $20.24 $2,449 - $3,744	-185 Reduced 5.02%	3,500 $50,000

Q4 2021 Feb 14, 2022	BUY	$15.44 - $27.32 $2,856 - $5,054	185 Added 5.29%	3,685 $73,000
Q3 2021 Nov 15, 2021	BUY	$20.7 - $34.69 $65,142 - $109,169	3,147 Added 891.5%	3,500 $76,000
Q2 2021 Aug 13, 2021	BUY	$18.58 - $25.37 $6,558 - $8,955	353 New	353 $9,000

Others Institutions Holding JANX

# of Institutions

123

Shares Held

25.3M

Call Options Held

92K

Put Options Held

161K

Orbimed Advisors LLC San Diego, CA

4.28M
Shares

$179 Million
3.62% of portfolio
Bvf Inc San Francisco, CA

2.92M
Shares

$122 Million
3.29% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

2.78M
Shares

$116 Million
0.2% of portfolio
Ken Griffin Citadel Advisors LLC | Chicago, Il

2.35M
Shares

$98.5 Million
0.02% of portfolio
Janus Henderson Group PLC London, X0

1.97M
Shares

$82.3 Million
0.04% of portfolio

View Full List

About Janux Therapeutics, Inc.

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $1.75B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

More about JANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account